Leukemia Research Foundation News

Leukemia Research Foundation earns top recognition from Charity Navigator

Northfield, IL (June 21, 2024) – The Leukemia Research Foundation is proud to announce that its strong financial health and ongoing accountability and transparency has earned another top Four-Star Rating from Charity Navigator.

Over the last decade the organization has received this high distinction numerous times, recognizing it as a “Give with Confidence” charity.  According to Charity Navigator, this indicates the organization is using donations effectively.

Charity Navigator, America’s largest and most-utilized independent charity evaluator, only awards four stars to the most exceptional organizations. Since 2001, the organization has been an unbiased and trusted source of information for more than 11 million donors annually.

“We are delighted to provide the Leukemia Research Foundation with third-party accreditation that validates their operational excellence,” said Michael Thatcher, President and CEO of Charity Navigator. “The Four-Star Rating is the highest possible rating an organization can achieve. We are eager to see the good work that the Leukemia Research Foundation is able to accomplish in the years ahead.”

“Our Four-Star Charity Navigator designation is further validation that our supporters can trust our commitment to good governance and financial health,” said Kevin Radelet, Executive Director, Leukemia Research Foundation. “We continue to be committed to a transparent approach in fulfilling our mission of funding research that breaks new ground in diagnosis and treatment, and in providing important resources that support patients and families.”

Detailed information about the Leukemia Research Foundation’s rating can be found on Charity Navigator’s website. To learn more about the Leukemia Research Foundation or to donate, visit their website at leukemiarf.org.

Subscribe

FDA Approves Iclusig Plus Chemo for Ph+ ALL

Blina may be effective in first-line treatment of Pediatric B-ALL

Pre-transplant gut microbiome may influence likelihood of GVHD